SLI
|
2 003,39
|
6,90
|
0,35 %
|
Analysen zu SLI-Werten
| 11.04.25 | Zurich Insurance Neutral | Goldman Sachs Group Inc. | |
| 11.04.25 | Givaudan Neutral | UBS AG | |
| 11.04.25 | Givaudan Hold | Deutsche Bank AG | |
| 11.04.25 | Givaudan Overweight | JP Morgan Chase & Co. | |
| 11.04.25 | Givaudan Buy | Goldman Sachs Group Inc. | |
| 10.04.25 | Zurich Insurance Underweight | JP Morgan Chase & Co. | |
| 10.04.25 | Givaudan Underperform | Jefferies & Company Inc. | |
| 10.04.25 | Zurich Insurance Overweight | Barclays Capital | |
| 10.04.25 | ABB Sell | Deutsche Bank AG | |
| 10.04.25 | UBS Buy | Deutsche Bank AG | |
| 10.04.25 | Swiss Re Overweight | JP Morgan Chase & Co. | |
| 10.04.25 | Givaudan Add | Baader Bank | |
| 10.04.25 | Givaudan Overweight | JP Morgan Chase & Co. | |
| 10.04.25 | Givaudan Underperform | Jefferies & Company Inc. | |
| 10.04.25 | Novartis Neutral | UBS AG | |
| 10.04.25 | Zurich Insurance Underweight | JP Morgan Chase & Co. | |
| 09.04.25 | Novartis Neutral | UBS AG | |
| 09.04.25 | UBS Hold | Jefferies & Company Inc. | |
| 09.04.25 | Richemont Hold | Deutsche Bank AG | |
| 08.04.25 | Richemont Overweight | JP Morgan Chase & Co. | |
| 08.04.25 | ams-OSRAM Buy | Deutsche Bank AG | |
| 08.04.25 | Richemont Buy | Jefferies & Company Inc. | |
| 08.04.25 | UBS Outperform | RBC Capital Markets | |
| 08.04.25 | ams-OSRAM Buy | Jefferies & Company Inc. | |
| 07.04.25 | Roche Buy | UBS AG | |
| 07.04.25 | Novartis Buy | Deutsche Bank AG | |
| 07.04.25 | Givaudan Add | Baader Bank | |
| 07.04.25 | Roche Sell | Deutsche Bank AG | |
| 07.04.25 | UBS Overweight | JP Morgan Chase & Co. | |
| 07.04.25 | ams-OSRAM Buy | Jefferies & Company Inc. | |
| 07.04.25 | Novartis Neutral | JP Morgan Chase & Co. | |
| 04.04.25 | Novartis Buy | Deutsche Bank AG | |
| 04.04.25 | Swiss Re Neutral | Goldman Sachs Group Inc. | |
| 04.04.25 | ABB Sector Perform | RBC Capital Markets | |
| 04.04.25 | Givaudan Overweight | JP Morgan Chase & Co. | |
| 03.04.25 | Roche Sell | Deutsche Bank AG | |
| 03.04.25 | Richemont Buy | UBS AG | |
| 03.04.25 | Novartis Buy | Deutsche Bank AG | |
| 03.04.25 | Novartis Outperform | Bernstein Research | |
| 03.04.25 | Roche Outperform | Bernstein Research |
Analysen zu Aktien folgender Indizes
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.